Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.

Journal Article (Journal Article)

Rare and low frequency variants are not well covered in most germline genotyping arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international Ovarian Cancer Association Consortium (OCAC). Pooled association analyses were conducted at the variant and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common variants that represent or are in strong linkage disequilibrium (LD) with previously-identified signals at established loci reached traditional thresholds for exome-wide significance (P < 5.0 × 10 -  7). One of the most significant signals (Pall histologies = 1.01 × 10 -  13;Pserous = 3.54 × 10 -  14) occurred at 3q25.31 for rs62273959, a missense variant mapping to the LEKR1 gene that is in LD (r2 = 0.90) with a previously identified 'best hit' (rs7651446) mapping to an intron of TIPARP. Suggestive associations (5.0 × 10 -  5 > P≥5.0 ×10 -  7) were detected for rare and low-frequency variants at 16 novel loci. Four rare missense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR = 9.66). Genes most strongly associated with EOC risk included ACTBL2 (PAML = 3.23 × 10 -  5; PSKAT-o = 9.23 × 10 -  4) and KRT13 (PAML = 1.67 × 10 -  4; PSKAT-o = 1.07 × 10 -  5), reaffirming variant-level analysis. In summary, this large study identified several rare and low-frequency variants and genes that may contribute to EOC susceptibility, albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional assays are needed to further unravel the unexplained heritability and biology of this disease.

Full Text

Duke Authors

Cited Authors

  • Permuth, JB; Pirie, A; Ann Chen, Y; Lin, H-Y; Reid, BM; Chen, Z; Monteiro, A; Dennis, J; Mendoza-Fandino, G; AOCS Study Group, ; Australian Cancer Study (Ovarian Cancer), ; Anton-Culver, H; Bandera, EV; Bisogna, M; Brinton, L; Brooks-Wilson, A; Carney, ME; Chenevix-Trench, G; Cook, LS; Cramer, DW; Cunningham, JM; Cybulski, C; D'Aloisio, AA; Anne Doherty, J; Earp, M; Edwards, RP; Fridley, BL; Gayther, SA; Gentry-Maharaj, A; Goodman, MT; Gronwald, J; Hogdall, E; Iversen, ES; Jakubowska, A; Jensen, A; Karlan, BY; Kelemen, LE; Kjaer, SK; Kraft, P; Le, ND; Levine, DA; Lissowska, J; Lubinski, J; Matsuo, K; Menon, U; Modugno, R; Moysich, KB; Nakanishi, T; Ness, RB; Olson, S; Orlow, I; Pearce, CL; Pejovic, T; Poole, EM; Ramus, SJ; Anne Rossing, M; Sandler, DP; Shu, X-O; Song, H; Taylor, JA; Teo, S-H; Terry, KL; Thompson, PJ; Tworoger, SS; Webb, PM; Wentzensen, N; Wilkens, LR; Winham, S; Woo, Y-L; Wu, AH; Yang, H; Zheng, W; Ziogas, A; Phelan, CM; Schildkraut, JM; Berchuck, A; Goode, EL; Pharoah, PDP; Sellers, TA; Ovarian Cancer Association Consortium,

Published Date

  • August 15, 2016

Published In

Volume / Issue

  • 25 / 16

Start / End Page

  • 3600 - 3612

PubMed ID

  • 27378695

Pubmed Central ID

  • PMC5179948

Electronic International Standard Serial Number (EISSN)

  • 1460-2083

Digital Object Identifier (DOI)

  • 10.1093/hmg/ddw196


  • eng

Conference Location

  • England